The overall goal of the University of lowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Administration Core is to stimulate research in lymphoma and to expedite the translation of discoveries into new and better methods of prevention, detection, and treatment of lymphoma. The Administration Core has served well as the organizational hub of UI/MC SPORE during the prior funding periods. During the next grant period (years 11-15), it will continue to provide an organizational structure designed to coordinate the activities ofthe research projects, scientific ceres, and developmental programs (Developmental Research Program, Career Development Program) at both institutions. The Administration Core will be responsible for coordinating the function of the SPORE committees including the Executive Committee and the External Advisory Committee, Dr. George Weiner will serve as Director of the Administration Core, and Dr. Thomas Witzig as Co- Director. Weiner and Witzig functioned well as a team during the prior funding periods, and will continue to work collaboratively to provide oversight of SPORE activities. The Administration Core will 1) Provide leadership, organizational support, and financial management for UI/MC SPORE investigators;2) Coordinate communication and collaboration between lowa and Mayo, including support for exchange of ideas between investigators, design of new projects, conduct of translational research, and reporting of translational research findings;3) Provide information transfer to the scientific community and the public;4) Provide leadership and organizational support for internal and external review for UI/MC SPORE research projects;5) Provide the structure for the establishment and nurture of collaborations to facilitate and expand lymphoma research including interactions between lowa and Mayo;6) Work closely with SPORE patient advocates se that they are aware of the progress of the SPORE, and facilitate their ability to provide input at all levels;7) Foster trainee development;8) Communicate with the NCI.
The Administration Cere provides administrative support for all UI/MC SPORE research activities and assures there is excellent communication between lowa and Mayo, and all participating investigators and staff. The Administration Core also assures that patient advocates participate in videoconferences and annual retreats and are included in all key decisions. It is a necessary component for a successful SPORE.
|Johnston, Patrick B; LaPlant, Betsy; McPhail, Ellen et al. (2016) Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol 3:e309-16|
|Wongrakpanich, Amaraporn; Mudunkotuwa, Imali A; Geary, Sean M et al. (2016) Size-dependent cytotoxicity of copper oxide nanoparticles in lung epithelial cells. Environ Sci Nano 3:365-374|
|Ahmed, Kawther K; Geary, Sean M; Salem, Aliasger K (2016) Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine. J Pharm Sci 105:1173-9|
|Boddicker, Rebecca L; Razidlo, Gina L; Dasari, Surendra et al. (2016) Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood 128:1234-45|
|King, Rebecca L; Dao, Linda N; McPhail, Ellen D et al. (2016) Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. Am J Surg Pathol 40:36-43|
|Maurer, Matthew J; Jais, Jean-Philippe; GhesquiÃ¨res, HervÃ© et al. (2016) Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol 91:179-84|
|Parry, Helen Marie; Damery, Sarah; Hudson, Christopher et al. (2016) Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. Am J Hematol 91:776-81|
|Machiela, Mitchell J; Lan, Qing; Slager, Susan L et al. (2016) Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Hum Mol Genet 25:1663-76|
|Mambetsariev, Nurbek; Lin, Wai W; Stunz, Laura L et al. (2016) Nuclear TRAF3 is a negative regulator of CREB in B cells. Proc Natl Acad Sci U S A 113:1032-7|
|Kenderian, Saad Sirop; Habermann, Thomas M; Macon, William R et al. (2016) Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood 127:1960-6|
Showing the most recent 10 out of 313 publications